Evelo Biosciences, Inc. is a biotechnology company that focuses on discovering and developing oral biologics for treating inflammatory diseases and cancer. The company is developing several potential treatments such as EDP1815, EDP1867, EDP2939, and EDP1908, with some already in Phase 2 clinical trials for inflammatory diseases, COVID-19, and oncology. Headquartered in Cambridge, Massachusetts, Evelo Biosciences, Inc. was incorporated in 2014.